Clinical trial of MVI 816 in combination with a PD-1 pathway inhibitor for the treatment of prostate cancer.
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2016
Price : $35 *
At a glance
- Drugs MVI 816 (Primary) ; Pembrolizumab (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 08 Nov 2016 According to a Madison Vaccines media release, this trial will guide expanded trials for treating late-stage cancers.
- 08 Nov 2016 Interim results published in the Madison Vaccines Media Release.
- 27 Oct 2016 According to a Madison Vaccines media release, data from this trial will be presented at the at the Society for Immunotherapy of Cancer annual meeting in November.